Nanjing Novlead Biotechnology (NVLD HK)

Nanjing Novlead Biotechnology, incorporated in 2018, operates in the gas-based cardiopulmonary device market, focusing on inhaled nitric oxide (iNO) therapy. The company is seeking to list on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules, with its Core Product, iNOwill, approved by the NMPA in 2022 and EU CE certified in 2025.